Amarin Outperforms Medical Stocks with 56% YTD Gain

Amarin (AMRN) has outperformed the Medical sector with a year-to-date return of 56%, compared to an average loss of 6.1% for the sector. Its Zacks Rank of #2 (Buy) and increased full-year earnings estimate have contributed to its positive outlook. The stock belongs to the Medical - Biomedical and Genetics industry, which has gained 0.2% this year. Amarin is also outperforming Bayer Aktiengesellschaft (BAYRY), another Medical stock that has returned 63.1% this year.

Amarin Corporation (AMRN) has demonstrated strong performance in the first half of 2025, significantly outperforming its peers within the Medical sector. As of July 2, 2025, AMRN has returned 56% year-to-date, compared to an average loss of 6.1% for the sector [1]. This robust performance can be attributed to several key factors, including its Zacks Rank of #2 (Buy) and an improved full-year earnings estimate.

The company's second-quarter 2025 results, released on July 30, highlighted its resilience. Amarin reported a loss of 3 cents per share, which was narrower than the Zacks Consensus Estimate of 66 cents per share. Adjusted earnings of 4 cents per share, excluding stock-based compensation and other expenses, marked a significant improvement over the year-ago quarter's adjusted earnings of 1 cent per share [1]. Total revenues reached $72.7 million, beating the Zacks Consensus Estimate of $46 million and increasing by 8% from the year-ago quarter [1].

Amarin's success can be attributed to its strategic licensing and royalty revenues, which increased by 31% year-over-year to $26.1 million. This growth was driven by the recognition of an upfront payment under the European licensing and supply agreement with Recordati, a key milestone in the company's expansion [1]. Additionally, the company's global restructuring is expected to deliver approximately $70 million in cost savings over the next 12 months [1].

In terms of industry positioning, Amarin belongs to the Medical - Biomedical and Genetics industry, which has gained 0.2% year-to-date. This sector-wide growth underscores the broader industry's positive outlook, with Amarin leading the pack. Notably, Amarin is also outperforming Bayer Aktiengesellschaft (BAYRY), another Medical stock that has returned 63.1% year-to-date [2].

Investors should continue to monitor Amarin's performance and the broader Medical sector. The company's strategic partnerships and cost-saving initiatives position it well for future growth, while its strong earnings outlook and sector outperformance make it an attractive investment opportunity.

References:
[1] https://www.theglobeandmail.com/investing/markets/stocks/CRMD-Q/pressreleases/33784729/amarin-s-q2-earnings-revenues-trump-estimates-stock-rises/
[2] https://finviz.com/news/130063/is-amarin-amrn-outperforming-other-medical-stocks-this-year